ArticleMediators of inflammation2026
Association of Life's Crucial 9 Score With Liver Fibrosis and Mortality in U.S. Adults With MASLD: Evidence From NHANES and the Mediating Role of Systemic Inflammation.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly prevalent. Life's Crucial 9 (LC9) combines cardiometabolic and mental health metrics linked to MASLD pathogenesis, but its association with liver fibrosis and prognosis in MASLD remains unknown.
methodsUsing National Health and Nutrition Examination Survey (NHANES) data, we performed a prospective cohort analysis for mortality (2005-2016, n = 2524) and a cross-sectional analysis for liver fibrosis (2017-2018, n = 1277). Significant fibrosis was defined as liver stiffness measurement (LSM) ≥8.0 kPa by vibration-controlled transient elastography. Systemic inflammation was assessed using the systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV). Multivariable regression and mediation analyses were conducted.
resultsHigher LC9 scores were associated with lower liver stiffness (β = -0.07, 95% CI: -0.12 to -0.01). Each 1-point increase in LC9 reduced fibrosis risk by 5% (OR = 0.95), with the highest quartile showing the lowest risk (OR = 0.21). Over a median follow-up of 98 months, each 1-point LC9 increase was associated with a 3% reduction in all-cause mortality (HR = 0.97). Lower systemic inflammation partially mediated the LC9-mortality relationship (SII: 5%, PIV: 6.3%).
conclusionHigher LC9 scores are associated with reduced liver fibrosis and improved survival in MASLD, with systemic inflammation partially mediating the mortality association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.